Podcasts about blue cross blue shield

Welcome to Episode 1 of the Fix SLP Summer School series—where we're schooling the system all summer long. Preston Lewis, MS/SLP, and private practice owner Elizabeth Nielsen, MA/SLP, tackle a key question: Do you really need the CCC in private practice? Elizabeth shares how dropping the CCC had zero impact on billing, referrals, or her waitlist—even with major payers like Blue Cross Blue Shield.They also break down ASHA's livestream response to the CMS rule changes, discuss tone policing in advocacy, and introduce Fix SLP's action plan: a letter to CMS Administrator Dr. Oz requesting a two-year delay. This episode is for private practitioners, Clinical Fellows, and anyone rethinking the CCC. Download your letter and take action at fixslp.com.Want to earn some PDHs or CEUs with a discount? Find our most up-to-date promo codes and discounts here.Want to lead or join your state team? Email your name and state to states@fixslp.com.Become a sustaining partner to support our work.Follow us on Instagram, Facebook, and TikTokFind all our information at fixslp.com, and sign up for our email list to be alerted to new episodes and content.Email us at team@fixslp.com.Leave a message on our Minivan Meltdown line! ★ Support this podcast ★

Beyond Busyness: How to Achieve More by Doing Less by Peggy Sullivan Amazon.com Peggysullivanspeaker.com “Too many people have fallen into the busy cycle that Peggy so accurately and honestly portrays. This book is the wakeup call you need to get back to living.” — Seth Godin, author of The Song of Significance FINALIST FOR THE 2024 BOOK EXCELLENCE AWARD FOR WOMEN'S HEALTH Busy is not better. Break the cycle of “just getting stuff done.” If you're feeling unfulfilled at the end of each day because you are busy but never seem to have time for what truly matters (a phenomenon called time poverty), you're not alone. As a recovering “busyness addict,” corporate performance expert Peggy Sullivan's struggle with the cycle of burnout and anxiety—leading to divorce, two totaled cars, a heart attack, and even accidentally eating cat food—led her on a quest for life outside busy . . . a sweet spot where productivity, happiness, and self-care can coexist. Her search led her to create a transformative framework for taking back control of your time and your life that has helped individuals, entrepreneurs, nonprofits, small businesses, and Fortune 500 companies such as Google, Bank of America, and Blue Cross Blue Shield get their employees off the busy treadmill and align their time and work with what's truly important. Grounded in deep research, including the results of a first-of-its-kind 2023 Busy Report, her three-step Busy-Busting Process has been proven to eliminate unintentional busyness, ignite the power of happiness, and unlock a more meaningful life. Beyond Busyness provides a simple, data-backed, and actionable approach to balancing peak performance, self-care, and happiness without sacrificing one for the other. About the author Peggy is a keynote speaker, author, consultant, and trusted researcher. Through her work, she has discovered why busyness is so detrimental to our productivity, health and happiness. Now she's bringing her proven solution for escaping the busyness trap to keynote stages around the world with her signature blend of humor, heart, and honesty. She is on a mission to help individuals and businesses move above the damaging false belief that “busy” always equates to success. With her help, people and organizations are unlocking peak performance, improving self-care, and finding true happiness, without sacrificing one for the other. Peggy has presented for small teams as well as Fortune 500 companies like Google, Bank of America, Blue Cross BlueShield, and Ingram Micro. In her forthcoming book “Beyond Busyness: How to Achieve More by Doing Less,” Peggy outlines her signature three-step "Busy Busting" methodology that is actionable, effective and has already helped thousands of people get off the busy treadmill to live the life they were meant to live.

Most medical care is backed by varying types of evidence, yet we apply higher standards to digital health tools before they're trusted, adopted, or reimbursed.In this special episode, guest host Lucia Savage is joined by Dr. Vindell Washington of Verily and Dr. Aaron Carroll of AcademyHealth for a candid conversation about the uneven standards we apply to digital versus traditional care. Together, they explore how we define evidence, whose voices shape that definition, and what it takes to build trust in an AI-powered healthcare future.We cover:

Bobby and Jared discuss the latest crazy issue Jared had with Blue Cross Blue Shield and the pediatrician, another debacle with UHaul, everyone dying at the same time, and making cast iron pizza/focaccia. Make sure you SUBSCRIBE to the show to stay up to date on the latest releases! You can also find the video show on YouTube by clicking here.Make sure you check out LMNT electrolyte drink mix at drinklmnt.com! Use the following link to get a FREE variety pack with your first purchase! http://elementallabs.refr.cc/jaredmello Thank you to our sponsor MoonBrew! Go to www.noonbrew.com/jaredmello for 10% off your entire purchase!

Brian D. Pieninck didn't take a conventional path to healthcare leadership. He started his career as an 18-year-old IT contractor and spent two decades working across the industry before becoming President and CEO of CareFirst Blue Cross Blue Shield. He now also serves as Chair of the Blue Cross Blue Shield Association, bringing both local and national perspective to the role. In this episode, Keith Figlioli speaks with Pieninck about what it means to lead a not-for-profit regional payer at a time of seismic change. With 3.6 million members and coverage that spans commercial, Medicare, and Medicaid, CareFirst has become a vital part of healthcare access and infrastructure across the Mid-Atlantic. Pieninck reflects how demographic shifts, rising costs, and policy uncertainty are challenging how healthcare organizations evolve, while staying focused on long-term outcomes.  Pieninck and Keith discuss: Advancing health equity as part of the community. Pieninck sees CareFirst not just as a payer, but as part of the region's civic infrastructure, creating economic opportunities, delivering care through primary and urgent care locations, and supporting long-term health equity initiatives across Maryland, DC, and Northern Virginia. Medicaid coverage and its downstream impact. With nearly half of children in Maryland and DC relying on Medicaid, Pieninck warns that cuts or disruptions don't reduce the need for care; they push it into higher-cost, less coordinated settings like emergency departments. The balloon effect in healthcare financing. As costs are squeezed in one area, they inflate in another. Pieninck challenges the idea that market forces can realign care efficiently. He discusses how efforts to contain spending in one area often lead to inefficiencies elsewhere, and the system ends up paying more later because early, lower-cost interventions are underfunded or inaccessible.  Innovation that simplifies the system. Through CareFirst's innovation arm, Healthworx, Pieninick highlights the need to design a system that works for people by reducing complexity and embedding support directly into the healthcare experience. AI and infrastructure: opportunity meets readiness. With nearly three decades of experience on the technology side of healthcare, Pieninck is bullish on AI's potential—especially now that it's available at a price point that can scale. Real progress, he notes, will depend on thoughtful governance, better interoperability, and models built around human needs. This episode offers a look at how one regional plan is thinking through the tensions between access, affordability and innovation, and what that means for the broader system.  To hear Brian D. Pieninck and Keith discuss these challenges in depth, listen to this episode of Healthcare is Hard: A Podcast for Insiders. 

James Harenchar is the President & CEO of Response Marketing Group, a consumer-data-focused marketing agency in Richmond, Va. As such, he is responsible for relationship development and account strategy at the independent agency, which offers marketing strategy/planning, data analytics, and interactive services. The agency serves many clients in the financial services, tourism, and healthcare sectors. RMG was founded in 1986 and their approach is consistent with the success gleaned from 35+ years of experience – data insights married to relevant messaging to the target audience. They are channel-neutral and work with select clients to define the KPIs that will drive revenue growth, customer growth, and increased asset values. They have developed several proprietary Ad Tech solutions that have introduced game-changing outcomes for DMOs across the US. In addition to serving as CEO, Jim leads the Travel and Tourism practice for RMG, which includes clients such as Arkansas Tourism, Georgia Tourism, Visit Savannah, Crested Butte, The Ritz Carlton, and The Resort Hotel Association among others. He is a thought leader within the tourism sector and a frequent speaker at the Southeast Tourism Society conference, Forrester Marketing Conference, Ad Federation, DestiCon, and Gartner. Prior to Response Marketing Group, Jim was Senior Vice President at The Allant Group in Chicago, IL from 2010-2014. He led the Strategic Consulting practice that delivered marketing strategy and high-level research to CMOs and brand managers at clients such as GM, Comcast, Nationwide Insurance, US Tennis Association, US Cellular, Blue Cross/Blue Shield, and Wells Fargo. Connect with Jon Dwoskin: Twitter: @jdwoskin Facebook: https://www.facebook.com/jonathan.dwoskin Instagram: https://www.instagram.com/thejondwoskinexperience/ Website: https://jondwoskin.com/LinkedIn: https://www.linkedin.com/in/jondwoskin/ Email: jon@jondwoskin.com Get Jon's Book: The Think Big Movement: Grow your business big. Very Big!   Connect with James Harenchar: Website: www.rmg-usa.com X: https://www.twitter.com/RMG_USA_VA LinkedIn: https://www.linkedin.com/in/jharenchar/ Facebook: https://www.facebook.com/rmgusallc                                     *E – explicit language may be used in this podcast.

Affordability isn't just about medical bills—it's about addressing what drives health in the first place. When people have stable housing, access to healthy food and support for mental health, they use the health care system less and live healthier lives. In this episode we explore how health care affordability starts far upstream—from food security and housing stability to behavioral health and chronic disease prevention. This episode will spotlight community-based partnerships that Blue Cross Blue Shield of Michigan has invested in to address these social determinants of health and ultimately reduce unnecessary costs across the system. Key Takeaways: · Community health is affordability. · Blue Cross is investing in upstream solutions that work toward health care affordability, access to health care and a healthier Michigan · Partnerships are scalable and sustainable. · Data backs this approach. · The future of affordability depends on partnership.

JCO Editorial Fellow Dr. Lauren Shih and JCO Associate Editor Dr. Stephanie Wheeler discuss the ASCO 25 Simultaneous Publication paper "Use of Low-Value Cancer Treatments in Medicare Advantage Versus Traditional Medicare." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Lauren Shih: Hello, and welcome to our 2025 ASCO annual meeting series where we cover some of the top JCO papers published simultaneously with their abstract presentations at this year's meeting. I'm your host, Dr. Lauren Shih, JCO editorial fellow, and I'm joined by JCO Associate Editor Dr. Stephanie Wheeler to discuss the Journal of Clinical Oncology article and abstract presentation "Use of Low-Value Cancer Treatments in Medicare Advantage Versus Traditional Medicare." Let's start with the relevance of the article. Dr. Wheeler, can you explain this to our listeners? Dr. Stephanie Wheeler: Thank you so much. Let's get right into it. So this article is really about understanding different types of Medicare plans and what we should expect to see in terms of their use of low-value treatments for cancer patients. So, as Medicare really is focused on trying to limit the use of low-value cancer treatments, we really need to better understand the drivers of variability. So we know that many cancer patients have multiple treatment options available to them. We also know that the vast majority of older adults beyond age 65 are insured by Medicare, and about half of them are on Medicare Advantage plans, which are serviced by private insurance. And private insurance companies in this case are receiving capitated payments for Medicare beneficiaries to manage their service utilization and reduce costs. So, with respect to Medicare Advantage versus the traditional fee-for-service Medicare, it's not really been known to what extent low-value treatments are differentially used by these types of plans for cancer patients. And so that was really the focus of this article. What the authors found is that across six different types of treatments, in general, the folks who were enrolled in Medicare Advantage plans had reduced use of low-value treatment. So that's a good sign for Medicare beneficiaries. And although the relative difference in that use was somewhat low, this translates to a significant number of Medicare enrollees across the country not receiving these low-value treatments. And of course, this translates to considerable savings at the society level. Dr. Lauren Shih: Are there any additional key results that we should review? Dr. Stephanie Wheeler: Yeah. So I'll tell you just a little bit more about the methods and also their findings. So they looked at six different low-value treatments, and this was in, again, 100% of national Medicare enrollees from 2015 through 2021. So the six low-value treatments that they examined were the use of G-CSFs among patients receiving low-risk chemotherapy and denosumab for those who had castration-sensitive prostate cancer. Then they also looked at four high-cost treatments, including using nab-paclitaxel instead of paclitaxel for patients with breast or lung cancer; second, adding bevacizumab to carboplatin plus paclitaxel for ovarian cancer; third, using brand-name drugs instead of generics when generics were available; and fourth, using biologics instead of biosimilars when biosimilars were available. And these are all, by the way, non-recommended treatments according to a variety of guidelines, including NCCN and ASCO's Choosing Wisely guidelines. So they used the Medicare claims data to examine use of these regimens. They also analyzed results by type of Medicare Advantage plan, whether people were enrolled in a health maintenance organization plan, or an HMO, or a preferred provider organization plan, or a PPO. They also looked at the largest Medicare Advantage insurers—including Aetna, Blue Cross Blue Shield, Cigna, Humana, and UnitedHealth—and limited their analyses to those that had complete encounter data. And what they found across the board is that the enrollees in Medicare Advantage plans generally had lower use of these low-value treatments. And the largest differences between Medicare Advantage and traditional Medicare plans were in the outcomes, including G-CSF use and using denosumab for castration-resistant prostate cancer, and then the combination of bevacizumab, carboplatin, and paclitaxel versus carboplatin and paclitaxel. And all of these had a change in use ranging from about 19% change to 24% change in use. This is significant as a field as we look at ways in which different plan organization can influence use of treatments, particularly given the excess cost of cancer care. This is something we really want to pay attention to. So I'd encourage folks to look more closely at the results by treatment type as well as the results by plan type to see a little bit more about what was going on across different plan types. Dr. Lauren Shih: Great. And are there any outstanding questions that need to be answered? Dr. Stephanie Wheeler: Yes, there always are, of course. I think the study has several strengths that are worth noting. First, they have 100% of Medicare enrollees, so there's national coverage there, which is, you know, quite outstanding. They also use an appropriate choice of analysis to help deal with some of the selection. So they use inverse probability of treatment weights, and they control for practice and county indicators to try to get some realistic adjustment for the selection that happens in terms of how patients are enrolled in different Medicare Advantage versus traditional fee-for-Medicare plans. These statistical approaches are a good idea, but they are limited by the observed variables that we can use for these kinds of adjustments. And so any unobserved—confounding or any unobserved factors that would influence selection in these plans aren't going to be captured well. So preferences, for example, that patients may have about different types of plans when they're insuring themselves and their families may not be captured. Second, the data that are used are only encounter data from those plans with complete records. That may mean that smaller Medicare Advantage insurers or those that don't have as comprehensive records are not included. So this may not be reflective of their practice patterns. And then third, of course, this only looked at six different low-value cancer treatments. It remains to be seen whether this kind of finding extends to other types of low-value cancer treatments, and that's an opportunity for future study. Finally, I would say that we don't exactly know why these patterns exist. It could be that Medicare Advantage plans have different approaches to prior authorization. They could have more in-house quality control and management to really understand, among their population for whom they're receiving Medicare Advantage payments, to really look at care quality and assess Choosing Wisely guidelines. We don't know exactly how that's playing out. And so we need additional data to really figure out what's working here and what are opportunities for future policy and payment innovations that can further reduce low-value care. Dr. Lauren Shih: Great. Thank you so much, Dr. Wheeler, for speaking to us about the JCO article, "Use of Low-Value Cancer Treatments in Medicare Advantage Versus Traditional Medicare." We really appreciate your insights. Dr. Stephanie Wheeler: Thanks for having me. Dr. Lauren Shih: Join us again for the latest simultaneous publications from the ASCO 2025 Annual Meeting. Please take a moment to rate, review, and subscribe to all ASCO podcast shows at asco.org/podcasts. Until then, enjoy the rest of ASCO 2025. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Goats, graduate degrees, and Glassdoor—yep, they're all part of Amber Cerone's leadership journey! From project manager to Senior Director of Talent and Doctor of Psychology, Amber's path is proof that “searching” is part of the process. In this episode, Amber joins Matt Poepsel to talk about the power of career exploration, why leadership is more about influence than titles, and how trust—not office time—drives engagement in a virtual world

On this episode of Empowering Workplaces we welcome Lynn Merritt, CHRO at Blue Cross Blue Shield Association. Lynn shares with us how she's creating a culture of trust, transparency, and inclusion across a huge network of community-focused healthcare organizations. With 20+ years in healthcare HR, she shares the ups and downs of piloting initiatives like a four-day workweek pilot, why really listening to employees matters, and how being authentic keeps teams engaged and motivated.Join hosts Sanja Licina, PhD, and Guille Santana for this inspiring conversation full of real talk about making work better and more meaningful. Plus, Lynn's top tips for HR leaders trying to do the same.

Let's talk about the C-word: Caregiving. In this episode, we continue our monthly series, NEXT AGE, with stories of people who are caring for an older adult relative. If you're thinking "who cares?" —  this might make you feel differently:According to a report from the National Alliance for Caregiving, for every five people you know, at least one of them is caring for a family member and even more are caring for more than one relative. They are unpaid — often unseen and sacrificing well-being, finances and identity.Caregiving is now a universal experience impacting every age, gender, socioeconomic and racial or ethnic group. In the words of the late former first lady Rosalyn Carter: “There are only four kinds of people in the world:Those who have been caregivers.Those who are currently caregivers.Those who will be caregivers,And those who will need a caregiver.” It can be a rewarding experience; but it can also be a physical, financial and emotional struggle.This episode will share stories of local people caring for an older adult relative. We'll hear from aging advocates about services and support systems for family caregivers, learn about options for longterm care allowing people to age at home, and we'll find out the latest research on strategies for coping and finding well-being.Our show is made possible by BlueCross BlueShield of Tennessee and our series on aging is made possible by a grant from The West End Home Foundation — enriching the lives of older adults though grantmaking, advocacy and community collaboration.This episode was produced by LaTonya Turner.GUESTS: Kenya Watkins, Family Caregiver Tiffany Cloud-Mann, Eldercare Coach/AgeWell Middle Tennessee Keri Pagetta, Sandwich Generation caregiver Dr. Feylyn Lewis, Caregiving Researcher / Dean of Student Affairs, Vanderbilt  University School of Nursing William Zagorski, Executive Director / Centennial Adultcare Center

May 28, 2025 ~ Tricia Keith, President and Chief Executive Officer of Blue Cross Blue Shield of Michigan joins Paul live from the Mackinac Policy Conference.

In this episode Lissa talks with author Rickey Fayne about deep philosophical questions inspired by his latest novel The Devil Three Times (Hachette Book Group, May 2025). Rickey Fayne is a fiction writer from rural West Tennessee whose work has appeared in American Short Fiction, Guernica, The Sewanee Review, and The Kenyon Review, among other magazines. He holds an MA in English from Northwestern University and an MFA in Fiction from the Michener Center for Writers at the University of Texas. His writing embodies his Black, Southern upbringing in order to reimagine and honor his ancestors' experiences. This episode was recorded at Magers & Quinn Booksellers in Minneapolis, MN. Visit www.BlackMarketReads.com   Our production team for this episode includes co-producers Lissa Jones and Edie French, technical director Paul Auguston, the voice Yo Derek, and our artist of inspiration Ta-coumba T. Aiken. We thank Blue Cross Blue Shield of Minnesota for supporting this series focusing on the intersection of health, race, and culture.

Ryan SchwoebelMS, College of Arts and Sciences, 2004Investigator, BlueCross/BlueShield of AlabamaAdjunct Instructor, UABMore InformationLinkedInFraud in government: A simulated investigation of a real-world case (manuscript)ABC 33/40 - Birmingham woman denied bonus at work to plead guilty for embezzling over $200,000WBRC - Do's and don'ts of using public Wi-FiInfraGard - February IBMA Chapter Meeting: China's Counterintelligence Threat to Corporate America

Send us a textIn this episode of the Advancing Surgical Care Podcast, ASCA Chief Executive Officer Bill Prentice talks with Robert Saltaformaggio, senior counsel at Liles Parker, a Washington, DC-based law firm that focuses on regulatory healthcare compliance and reimbursement issues. Saltaformaggio is also a certified professional coder who assists ASCs and other healthcare providers with Medicare and Medicaid payer coverage and payment requirements, as well as claims disputes with major payers such as the various Blue Cross Blue Shield entities and UnitedHealthcare. During their discussion, Prentice and Saltaformaggio talk about the current regulatory landscape, the role of AI, the importance of conducting self-audits and more.

Host Saeed Khan talks with attorneys Steve Fishman, Joel Sklar and Bill Seikaly, public relations specialist Beverly Watts, labor and community activist Barb Ingalls, veteran journalist Nancy Derringer and Deadline Detroit co-founder Allan Lengel.They talk about: U.S. and China agree to slash most tariffs… for Now;  Trump set to receive luxury Boeing 747 from Qatar as Air Force one replacement/gift;  Trump's Middle East visit; India and Pakistan agree to a ceasefire after dangerous military exchanges;  U-M regent ties to Blue Cross-Blue Shield raises concerns about potential conflict of interest;  Pete Rose and Shoeless Joe Jackson cleared to be considered for Major League Baseball Hall of Fame and Schmuck of the Week. 

In this episode of Investor Connect, we welcome Alan Foreman, the CEO of Be Secure, who discusses the transformative journey of his company in the realm of heart health. Alan shares that he founded Be Secure nine years ago after a lengthy career in Accenture's Life Sciences division. Currently, the company is on a $12 million growth raise to commercialize its breakthrough heart health technology, which received FDA clearance recently. Be Secure focuses on making preventive rather than reactive heart health solutions, leveraging their powerful, device-agnostic software that offers high accuracy ECG readings in consumer and medical devices alike, such as the latest versions of the Whoop and Fitbit devices. Alan elaborates on how the recent challenges faced by Philips, a significant player in heart monitoring technology, present both a testament to the need for better solutions and an opportunity for Be Secure to make a substantial impact on the market. Alan details the company's innovative use of cybersecurity experts and detailed signal processing to develop technology that bridges consumer wellness and medical-grade ECG technology. He highlights how Be Secure's cloud-based and on-device solutions offer transformative accuracy and efficiency in heart monitoring, even earning the interest of major insurers like Blue Cross Blue Shield. The conversation turns to the scalability and swift deployment of Be Secure's solutions in medical environments, emphasizing how their data quality can accelerate and improve diagnosis in cardiologists' workflows. Alan stresses the importance of their upcoming scale-up and commercial focus, particularly in filling the funding gap to expedite the deployment of their remarkable technology in the healthcare space. We also learn about Be Secure's financials and investment strategy, which involves contributions from venture capital and venture debt providers. Alan emphasizes ongoing discussions with top medical companies and the anticipated rapid revenue growth fueled by the latest FDA clearance. The episode wraps with Alan addressing some practical questions about scaling, design timelines, and the lifecycle of deals with their partners, giving a comprehensive view of Be Secure's promising future. For more updates and opportunities to engage with Alan and Be Secure, stay tuned to Investor Connect.    Thank you for joining us for the Startup Funding Espresso where we help startups and investors connect for funding. Let's go startup something today. _______________________________________________________ For more episodes from Investor Connect, please visit the site at:   Check out our other podcasts here:   For Investors check out:   For Startups check out:   For eGuides check out:   For upcoming Events, check out    For Feedback please contact info@tencapital.group    Please , share, and leave a review. Music courtesy of .

May 14, 2025 ~ Sarah Hubbard, University of Michigan Board of Regents Chair participated in closed-door meetings with university staff about a push to renegotiate hospital reimbursement rates paid by Blue Cross Blue Shield of Michigan. Craig Mauger joins Kevin to discuss the meeting.

Corey Thomas is the CEO and Chairman of Rapid7, a leading public cybersecurity software company valued around $3.5B. He is also an angel investor in several tech companies, a member of the Council on Foreign Relations, a director and deputy chair of the Federal Reserve Bank of Boston, and a member of the Blue Cross Blue Shield of Massachusetts board of directors, among other honors. Before Rapid7, Corey worked extensively at companies such as Microsoft, Deloitte, and AT&T. Corey joined host Robert Glazer on the Elevate Podcast to talk about his leadership approach, how he rose through the ranks at Fortune 500 companies, and much more. Special Thanks to the Sponsors of the Elevate Podcast Shopify: Sign up for your $1/month trial period at ⁠⁠⁠shopify.com/elevate⁠⁠⁠ Indeed: Get a $75 sponsored job credit to boost your job's visibility at ⁠⁠⁠Indeed.com/elevate⁠⁠⁠. Masterclass: Get an additional 15% off any annual membership at masterclass.com/elevate. Northwest Registered Agent: Don't wait—protect your privacy, build your brand, and set up your business in just 10 clicks and 10 minutes! Visit ⁠⁠⁠https://northwestregisteredagent.com/elevate⁠⁠⁠ today. Quince: Go to ⁠quince.com/elevate⁠ for free shipping on your order and 365-day returns Learn more about your ad choices. Visit megaphone.fm/adchoices

On this special edition of Rhode Island PBS Weekly we take an in-depth look at youth and mental health issues. All of our segments on this episode were generously underwritten by a grant from Blue Cross Blue Shield of Rhode Island. We begin with Michelle San Miguel's report on the mental health issues that many of the Ocean State's young people struggle with every day. And the role race and sexual orientation plays in their emotional wellbeing. Then, Isabella Jibilian has a report on loneliness and its detrimental physical and mental effects on both the young and the old here in Rhode Island and beyond. Finally, Isabella Jibilian explores how technology that is designed to be addictive can have tragic consequences for kids and teens.

Much has been made of the hallucinatory qualities of OpenAI's ChatGPT product. But as the Wall Street Journal's resident authority on OpenAI, Keach Hagey notes, perhaps the most hallucinatory feature the $300 billion start-up co-founded by the deadly duo of Sam Altman and Elon Musk is its attempt to be simultaneously a for-profit and non-profit company. As Hagey notes, the double life of this double company reached a surreal climax this week when Altman announced that OpenAI was abandoning its promised for-profit conversion. So what, I asked Hagey, are the implications of this corporate volte-face for investors who have poured billions of real dollars into the non-profit in order to make a profit? Will they be Waiting For Godot to get their returns?As Hagey - whose excellent biography of Altman, The Optimist, is out in a couple of weeks - explains, this might be the story of the hubristic 2020's. She speaks of Altman's astonishingly (even for Silicon Valley) hubris in believing that he can get away with the alchemic conceit of inventing a multi trillion dollar for-profit non-profit company. Yes, you can be half-pregnant, Sam is promising us. But, as she warns, at some point this will be exposed as fantasy. The consequences might not exactly be another Enron or FTX, but it will have ramifications way beyond beyond Silicon Valley. What will happen, for example, if future investors aren't convinced by Altman's fantasy and OpenAI runs out of cash? Hagey suggests that the OpenAI story may ultimately become a political drama in which a MAGA President will be forced to bail out America's leading AI company. It's TikTok in reverse (imagine if Chinese investors try to acquire OpenAI). Rather than the conveniently devilish Elon Musk, my sense is that Sam Altman is auditioning to become the real Jay Gatsby of our roaring twenties. Last month, Keach Hagey told me that Altman's superpower is as a salesman. He can sell anything to anyone, she says. But selling a non-profit to for-profit venture capitalists might even be a bridge too far for Silicon Valley's most hallucinatory optimist. Five Key Takeaways * OpenAI has abandoned plans to convert from a nonprofit to a for-profit structure, with pressure coming from multiple sources including attorneys general of California and Delaware, and possibly influenced by Elon Musk's opposition.* This decision will likely make it more difficult for OpenAI to raise money, as investors typically want control over their investments. Despite this, Sam Altman claims SoftBank will still provide the second $30 billion chunk of funding that was previously contingent on the for-profit conversion.* The nonprofit structure creates inherent tensions within OpenAI's business model. As Hagey notes, "those contradictions are still there" after nearly destroying the company once before during Altman's brief firing.* OpenAI's leadership is trying to position this as a positive change, with plans to capitalize the nonprofit and launch new programs and initiatives. However, Hagey notes this is similar to what Altman did at Y Combinator, which eventually led to tensions there.* The decision is beneficial for competitors like XAI, Anthropic, and others with normal for-profit structures. Hagey suggests the most optimistic outcome would be OpenAI finding a way to IPO before "completely imploding," though how a nonprofit-controlled entity would do this remains unclear.Keach Hagey is a reporter at The Wall Street Journal's Media and Marketing Bureau in New York, where she focuses on the intersection of media and technology. Her stories often explore the relationships between tech platforms like Facebook and Google and the media. She was part of the team that broke the Facebook Files, a series that won a George Polk Award for Business Reporting, a Gerald Loeb Award for Beat Reporting and a Deadline Award for public service. Her investigation into the inner workings of Google's advertising-technology business won recognition from the Society for Advancing Business Editing and Writing (Sabew). Previously, she covered the television industry for the Journal, reporting on large media companies such as 21st Century Fox, Time Warner and Viacom. She led a team that won a Sabew award for coverage of the power struggle inside Viacom. She is the author of “The King of Content: Sumner Redstone's Battle for Viacom, CBS and Everlasting Control of His Media Empire,” published by HarperCollins. Before joining the Journal, Keach covered media for Politico, the National in Abu Dhabi, CBS News and the Village Voice. She has a bachelor's and a master's in English literature from Stanford University. She lives in Irvington, N.Y., with her husband, three daughters and dog.Named as one of the "100 most connected men" by GQ magazine, Andrew Keen is amongst the world's best known broadcasters and commentators. In addition to presenting the daily KEEN ON show, he is the host of the long-running How To Fix Democracy interview series. He is also the author of four prescient books about digital technology: CULT OF THE AMATEUR, DIGITAL VERTIGO, THE INTERNET IS NOT THE ANSWER and HOW TO FIX THE FUTURE. Andrew lives in San Francisco, is married to Cassandra Knight, Google's VP of Litigation & Discovery, and has two grown children. Full TranscriptAndrew Keen: Hello, everybody. It is May the 6th, a Tuesday, 2025. And the tech media is dominated today by OpenAI's plan to convert its for-profit business to a non-profit side. That's how the Financial Times is reporting it. New York Times says that OpenAI, and I'm quoting them, backtracks on plans to drop nonprofit control and the Wall Street Journal, always very authoritative on the tech front, leads with Open AI abandons planned for profit conversion. The Wall Street Journal piece is written by Keach Hagey, who is perhaps America's leading authority on OpenAI. She was on the show a couple of months ago talking about Sam Altman's superpower which is as a salesman. Keach is also the author of an upcoming book. It's out in a couple weeks, "The Optimist: Sam Altman, OpenAI and the Race to Invent the Future." And I'm thrilled that Keach has been remarkably busy today, as you can imagine, found a few minutes to come onto the show. So, Keach, what is Sam selling here? You say he's a salesman. He's always selling something or other. What's the sell here?Keach Hagey: Well, the sell here is that this is not a big deal, right? The sell is that, this thing they've been trying to do for about a year, which is to make their company less weird, it's not gonna work. And as he was talking to the press yesterday, he was trying to suggest that they're still gonna be able to fundraise, that these folks that they promised that if you give us money, we're gonna convert to a for-profit and it's gonna be much more normal investment for you, but they're gonna get that money, which is you know, a pretty tough thing. So that's really, that's what he's selling is that this is not disruptive to the future of OpenAI.Andrew Keen: For people who are just listening, I'm looking at Keach's face, and I'm sensing that she's doing everything she can not to burst out laughing. Is that fair, Keach?Keach Hagey: Well, it'll remain to be seen, but I do think it will make it a lot harder for them to raise money. I mean, even Sam himself said as much during the talk yesterday that, you know, investors would like to be able to have some say over what happens to their money. And if you're controlled by a nonprofit organization, that's really tough. And what they were trying to do was convert to a new world where investors would have a seat at the table, because as we all remember, when Sam got briefly fired almost two years ago. The investors just helplessly sat on the sidelines and didn't have any say in the matter. Microsoft had absolutely no role to play other than kind of cajoling and offering him a job on the sidelines. So if you're gonna try to raise money, you really need to be able to promise some kind of control and that's become a lot harder.Andrew Keen: And the ramifications more broadly on this announcement will extend to Microsoft and Microsoft stock. I think their stock is down today. We'll come to that in a few minutes. Keach, there was an interesting piece in the week, this week on AI hallucinations are getting worse. Of course, OpenAI is the dominant AI company with their ChatGPT. But is this also kind of hallucination? What exactly is going on here? I have to admit, and I always thought, you know, I certainly know more about tech than I do about other subjects, which isn't always saying very much. But I mean, either you're a nonprofit or you're a for-profit, is there some sort of hallucinogenic process going on where Sam is trying to sell us on the idea that OpenAI is simultaneously a for profit and a nonprofit company?Keach Hagey: Well, that's kind of what it is right now. That's what it had sort of been since 2019 or when it spun up this strange structure where it had a for-profit underneath a nonprofit. And what we saw in the firing is that that doesn't hold. There's gonna come a moment when those two worlds are going to collide and it nearly destroyed the company. To be challenging going forward is that that basic destabilization that like unstable structure remains even though now everything is so much bigger there's so much more money coursing through and it's so important for the economy. It's a dangerous position.Andrew Keen: It's not so dangerous, you seem still faintly amused. I have to admit, I'm more than faintly amused, it's not too bothersome for us because we don't have any money in OpenAI. But for SoftBank and the other participants in the recent $40 billion round of investment in OpenAI, this must be, to say the least, rather disconcerting.Keach Hagey: That was one of the biggest surprises from the press conference yesterday. Sam Altman was asked point blank, is SoftBank still going to give you this sort of second chunk, this $30 billion second chunk that was contingent upon being able to convert to a for-profit, and he said, quite simply, yes. Who knows what goes on in behind the scenes? I think we're gonna find out probably a lot more about that. There are many unanswered questions, but it's not great, right? It's definitely not great for investors.Andrew Keen: Well, you have to guess at the very minimum, SoftBank would be demanding better terms. They're not just going to do the same thing. I mean, it suddenly it suddenly gives them an additional ace in their hand in terms of negotiation. I mean this is not some sort of little startup. This is 30 or 40 billion dollars. I mean it's astonishing number. And presumably the non-public conversations are very interesting. I'm sure, Keach, you would like to know what's being said.Keach Hagey: Don't know yet, but I think your analysis is pretty smart on this matter.Andrew Keen: So if you had to guess, Sam is the consummate salesman. What did he tell SoftBank before April to close the round? And what is he telling them now? I mean, how has the message changed?Keach Hagey: One of the things that we see a little bit about this from the messaging that he gave to the world yesterday, which is this is going to be a simpler structure. It is going to be slightly more normal structure. They are changing the structure a little bit. So although the non-profit is going to remain in charge, the thing underneath it, the for-profit, is going change its structure a little bit and become kind of a little more normal. It's not going to have this capped profit thing where, you know, the investors are capped at 100 times what they put in. So parts of it are gonna become more normal. For employees, it's probably gonna be easier for them to get equity and things like that. So I'm sure that that's part of what he's selling, that this new structure is gonna be a little bit better, but it's not gonna be as good as what they were trying to do.Andrew Keen: Can Sam? I mean, clearly he has sold it. I mean as we joked earlier when we talked, Sam could sell ice to the Laplanders or sand to the Saudis. But these people know Sam. It's no secret that he's a remarkable salesman. That means that sometimes you have to think carefully about what he's saying. What's the impact on him? To what extent is this decision one more chip on the Altman brand?Keach Hagey: It's a setback for sure, and it's kind of a win for Elon Musk, his rival.Andrew Keen: Right.Keach Hagey: Elon has been suing him, Elon has been trying to block this very conversion. And in the end, it seems like it was actually the attorneys general of California and Delaware that really put the nail in the coffin here. So there's still a lot to find out about exactly how it all shook out. There were actually huge campaigns as well, like in the streets, billboards, posters. Polls saying, trying to put pressure on the attorney general to block this thing. So it was a broad coalition, I think, that opposed the conversion, and you can even see that a little bit in their speech. But you got to admit that Elon probably looked at this and was happy.Andrew Keen: And I'm sure Elon used his own X platform to promote his own agenda. Is this an example, Keach, in a weird kind of way of the plebiscitary politics now of Silicon Valley is that titans like Altman and Musk are fighting out complex corporate economic battles in the naked public of social media.Keach Hagey: Yes, in the naked public of social media, but what we're also seeing here is that it's sort of, it's become through the apparatus of government. So we're seeing, you know, Elon is in the Doge office and this conversion is really happening in the state AG's houses. So that's what's sort interesting to me is these like private fights have now expanded to fill both state and federal government.Andrew Keen: Last time we talked, I couldn't find the photo, but there was a wonderful photo of, I think it was Larry Ellison and Sam Altman in the Oval Office with Trump. And Ellison looked very excited. He looked extremely old as well. And Altman looked very awkward. And it's surprising to see Altman look awkward because generally he doesn't. Has Trump played a role in this or is he keeping out of it?Keach Hagey: As far as my current reporting right now, we have no reporting that Trump himself was directly involved. I can't go further than that right now.Andrew Keen: Meaning that you know something that you're not willing to ignore.Keach Hagey: Just I hope you keep your subscription to the Wall Street Journal on what role the White House played, I would say. But as far as that awkwardness, I don't know if you noticed that there was a box that day for Masa Yoshison to see.Andrew Keen: Oh yeah, and Son was in the office too, right, that was the third person.Keach Hagey: So it was a box in the podium, which I think contributed to the awkwardness of the day, because he's not a tall man.Andrew Keen: Right. To put it politely. The way that OpenAI spun it, in classic Sam Altman terms, is new funding to build towards AGI. So it's their Altman-esque use of the public to vindicate this new investment, is this just more quote unquote, and this is my word. You don't have to agree with it. Just sales pitch or might even be dishonesty here. I mean, the reality is, is new funding to build towards AGI, which is, artificial general intelligence. It's not new funding, to build toward AGI. It's new funding to build towards OpenAI, there's no public benefit of any of this, is there?Keach Hagey: Well, what they're saying is that the nonprofit will be capitalized and will sort of be hiring up and doing a bunch more things that it wasn't really doing. We'll have programs and initiatives and all of that. Which really, as someone who studied Sam's life, this sounds really a lot like what he did at Y Combinator. When he was head of Y Combinator, he also spun up a nonprofit arm, which is actually what OpenAI grew out of. So I think in Sam's mind, a nonprofit there's a place to go. Sort of hash out your ideas, it's a place to kind of have pet projects grow. That's where he did things like his UBI study. So I can sort of see that once the AGs are like, this is not gonna happen, he's like, great, we'll just make a big nonprofit and I'll get to do all these projects I've always wanted to do.Andrew Keen: Didn't he get thrown out of Y Combinator by Paul Graham for that?Keach Hagey: Yes, a little bit. You know, I would say there's a general mutiny for too much of that kind of stuff. Yeah, it's true. People didn't love it, and they thought that he took his eye off the ball. A little bit because one of those projects became OpenAI, and he became kind of obsessed with it and stopped paying attention. So look, maybe OpenAI will spawn the next thing, right? And he'll get distracted by that and move on.Andrew Keen: No coincidence, of course, that Sam went on to become a CEO of OpenAI. What does it mean for the broader AI ecosystem? I noted earlier you brought up Microsoft. I mean, I think you've already written on this and lots of other people have written about the fact that the relationship between OpenAI and Microsoft has cooled dramatically. As well as between Nadella and Altman. What does this mean for Microsoft? Is it a big deal?Keach Hagey: They have been hashing this out for months. So it is a big deal in that it will change the structure of their most important partner. But even before this, Microsoft and OpenAI were sort of locked in negotiations over how large and how Microsoft's stake in this new OpenAI will be valued. And that still has to be determined, regardless of whether it's a non-profit or a for-profit in charge. And their interests are diverging. So those negotiations are not as warm as they maybe would have been a few years ago.Andrew Keen: It's a form of polyamory, isn't it? Like we have in Silicon Valley, everyone has sex with everybody else, to put it politely.Keach Hagey: Well, OpenAI does have a new partner in Oracle. And I would expect them to have many more in terms of cloud computing partners going forward. It's just too much risk for any one company to build these huge and expensive data centers, not knowing that OpenAI is going to exist in a certain number of years. So they have to diversify.Andrew Keen: Keach, you know, this is amusing and entertaining and Altman is a remarkable individual, able to sell anything to anyone. But at what point are we really on the Titanic here? And there is such a thing as an iceberg, a real thing, whatever Donald Trump or other manufacturers of ontologies might suggest. At some point, this thing is going to end in a massive disaster.Keach Hagey: Are you talking about the Existence Force?Andrew Keen: I'm not talking about the Titanic, I'm talking about OpenAI. I mean, Parmi Olson, who's the other great authority on OpenAI, who won the FT Book of the Year last year, she's been on the show a couple of times, she wrote in Bloomberg that OpenAI can't have its money both ways, and that's what Sam is trying to do. My point is that we can all point out, excuse me, the contradictions and the hypocrisy and all the rest of it. But there are laws of gravity when it comes to economics. And at a certain point, this thing is going to crash, isn't it? I mean, what's the metaphor? Is it Enron? Is it Sam Bankman-Fried? What kind of examples in history do we need to look at to try and figure out what really is going on here?Keach Hagey: That's certainly one possibility, and there are a good number of people who believe that.Andrew Keen: Believe what, Enron or Sam Bankman-Fried?Keach Hagey: Oh, well, the internal tensions cannot hold, right? I don't know if fraud is even necessary so much as just, we've seen it, we've already seen it happen once, right, the company almost completely collapsed one time and those contradictions are still there.Andrew Keen: And when you say it happened, is that when Sam got pushed out or was that another or something else?Keach Hagey: No, no, that's it, because Sam almost got pushed out and then all of the funders would go away. So Sam needs to be there for them to continue raising money in the way that they have been raising money. And that's really going to be the question. How long can that go on? He's a young man, could go on a very long time. But yeah, I think that really will determine whether it's a disaster or not.Andrew Keen: But how long can it go on? I mean, how long could Sam have it both ways? Well, there's a dream. I mean maybe he can close this last round. I mean he's going to need to raise more than $40 billion. This is such a competitive space. Tens of billions of dollars are being invested almost on a monthly basis. So this is not the end of the road, this $40-billion investment.Keach Hagey: Oh, no. And you know, there's talk of IPO at some point, maybe not even that far away. I don't even let me wrap my mind around what it would be for like a nonprofit to have a controlling share at a public company.Andrew Keen: More hallucinations economically, Keach.Keach Hagey: But I mean, IPO is the exit for investors, right? That's the model, that is the Silicon Valley model. So it's going to have to come to that one way or another.Andrew Keen: But how does it work internally? I mean, for the guys, the sales guys, the people who are actually doing the business at OpenAI, they've been pretty successful this year. The numbers are astonishing. But how is this gonna impact if it's a nonprofit? How does this impact the process of selling, of building product, of all the other internal mechanics of this high-priced startup?Keach Hagey: I don't think it will affect it enormously in the short term. It's really just a question of can they continue to raise money for the enormous amount of compute that they need. So so far, he's been able to do that, right? And if that slows up in any way, they're going to be in trouble. Because as Sam has said many times, AI has to be cheap to be actually useful. So in order to, you know, for it to be widespread, for to flow like water, all of those things, it's got to be cheap and that's going to require massive investment in data centers.Andrew Keen: But how, I mean, ultimately people are putting money in so that they get the money back. This is not a nonprofit endeavor to put 40 billion from SoftBank. SoftBank is not in the nonprofit business. So they're gonna need their money back and the only way they generally, in my understanding, getting money back is by going public, especially with these numbers. How can a nonprofit go public?Keach Hagey: It's a great question. That's what I'm just phrasing. I mean, this is, you know, you talk to folks, this is what's like off in the misty distance for them. It's an, it's a fascinating question and one that we're gonna try to answer this week.Andrew Keen: But you look amused. I'm no financial genius. Everyone must be asking the same question.Keach Hagey: Well, the way that they've said it is that the for-profit will be, will have a, the non-profit will control the for profit and be the largest shareholder in it, but the rest of the shares could be held by public markets theoretically. That's a great question though.Andrew Keen: And lawyers all over the world must be wrapping their hands. I mean, in the very best case, it's gonna be lawsuits on this, people suing them up the wazoo.Keach Hagey: It's absolutely true. You should see my inbox right now. It's just like layers, layers, layer.Andrew Keen: Yeah, my wife. My wife is the head of litigation. I don't know if I should be saying this publicly anyway, I am. She's the head of Litigation at Google. And she lost some of her senior people and they all went over to AI. I'm big, I'm betting that they regret going over there can't be much fun being a lawyer at OpenAI.Keach Hagey: I don't know, I think it'd be great fun. I think you'd have like enormous challenges and have lots of billable hours.Andrew Keen: Unless, of course, they're personally being sued.Keach Hagey: Hopefully not. I mean, look, it is a strange and unprecedented situation.Andrew Keen: To what extent is this, if not Shakespearean, could have been written by some Greek dramatist? To what extend is this symbolic of all the hype and salesmanship and dishonesty of Silicon Valley? And in a sense, maybe this is a final scene or a penultimate scene in the Silicon Valley story of doing good for the world. And yet, of course, reaping obscene profit.Keach Hagey: I think it's a little bit about trying to have your cake and eat it too, right? Trying to have the aura of altruism, but also make something and make a lot of money. And what it seems like today is that if you started as a nonprofit, it's like a black hole. You can never get out. There's no way to get out, and that idea was just like maybe one step too clever when they set it up in the beginning, right. It seemed like too good to be true because it was. And it might end up really limiting the growth of the company.Andrew Keen: Is Sam completely in charge here? I mean, a number of the founders have left. Musk, of course, when you and I talked a couple of months ago, OpenAI came out of conversations between Musk and Sam. Is he doing this on his own? Does he have lieutenants, people who he can rely on?Keach Hagey: Yeah, I mean, he does. He has a number of folks that have been there, you know, a long time.Andrew Keen: Who are they? I mean, do we know their names?Keach Hagey: Oh, sure. Yeah. I mean, like Brad Lightcap and Jason Kwon and, you know, just they're they're Greg Brockman, of course, still there. So there are a core group of executives that have that have been there pretty much from the beginning, close to it, that he does trust. But if you're asking, like, is Sam really in control of this whole thing? I believe the answer is yes. Right. He is on the board of this nonprofit, and that nonprofit will choose the board of the for-profit. So as long as that's the case, he's in charge.Andrew Keen: How divided is OpenAI? I mean, one of the things that came out of the big crisis, what was it, 18 months ago when they tried to push him out, was it was clearly a profoundly divided company between those who believed in the nonprofit mission versus the for-profit mission. Are those divisions still as acute within the company itself? It must be growing. I don't know how many thousands of people work.Keach Hagey: It has grown very fast. It is not as acute in my experience. There was a time when it was really sort of a warring of tribes. And after the blip, as they call it, a lot of those more safety focused people, people that subscribe to effective altruism, left or were kind of pushed out. So Sam took over and kind of cleaned house.Andrew Keen: But then aren't those people also very concerned that it appears as if Sam's having his cake and eating it, having it both ways, talking about the company being a non-profit but behaving as if it is a for-profit?Keach Hagey: Oh, yeah, they're very concerned. In fact, a number of them have signed on to this open letter to the attorneys general that dropped, I don't know, a week and a half ago, something like that. You can see a number of former OpenAI employees, whistleblowers and others, saying this very thing, you know, that the AG should block this because it was supposed to be a charitable mission from the beginning. And no amount of fancy footwork is gonna make it okay to toss that overboard.Andrew Keen: And I mean, in the best possible case, can Sam, the one thing I think you and I talked about last time is Sam clearly does, he's not driven by money. There's something else. There's some other demonic force here. Could he theoretically reinvent the company so that it becomes a kind of AI overlord, a nonprofit AI overlord for our 21st century AI age?Keach Hagey: Wow, well I think he sometimes thinks of it as like an AI layer and you know, is this my overlord? Might be, you know.Andrew Keen: As long as it's not made in China, I hope it's made in India or maybe in Detroit or something.Keach Hagey: It's a very old one, so it's OK. But it's really my attention overlord, right? Yeah, so I don't know about the AI overlord part. Although it's interesting, Sam from the very beginning has wanted there to be a democratic process to control what decision, what kind of AI gets built and what are the guardrails for AGI. As long as he's there.Andrew Keen: As long as he's the one determining it, right?Keach Hagey: We talked about it a lot in the very beginning of the company when things were smaller and not so crazy. And what really strikes me is he doesn't really talk about that much anymore. But what we did just see is some advocacy organizations that kind of function in that exact way. They have voters all over the world and they all voted on, hey, we want you guys to go and try to that ended up having this like democratic structure for deciding the future of AI and used it to kind of block what he was trying to do.Andrew Keen: What are the implications for OpenAI's competitors? There's obviously Anthropic. Microsoft, we talked about a little bit, although it's a partner and a competitor simultaneously. And then of course there's Google. I assume this is all good news for the competition. And of course XAI.Keach Hagey: It is good news, especially for a company like XAI. I was just speaking to an XAI investor today who was crowing. Yeah, because those companies don't have this weird structure. Only OpenAI has this strange nonprofit structure. So if you are an investor who wants to have some exposure to AI, it might just not be worth the headache to deal with the uncertainty around the nonprofit, even though OpenAI is like the clear leader. It might be a better bet to invest in Anthropic or XAI or something else that has just a normal for-profit structure.Andrew Keen: Yeah. And it's hard to actually quote unquote out-Trump, Elon Musk on economic subterfuge. But Altman seems to have done that. I mean, Musk, what he folded X into XAI. It was a little bit of controversy, but he seems to got away with it. So there is a deep hostility between these two men, which I'm assuming is being compounded by this process.Keach Hagey: Absolutely. Again, this is a win for Elon. All these legal cases and Elon trying to buy OpenAI. I remember that bid a few months ago where he actually put a number on it. All that was about trying to block the for-profit conversion because he's trying to stop OpenAI and its tracks. He also claims they've abandoned their mission, but it's always important to note that it's coming from a competitor.Andrew Keen: Could that be a way out of this seeming box? Keach, a company like XAI or Microsoft or Google, or that probably wouldn't happen on the antitrust front, would buy OpenAI as maybe a nonprofit and then transform it into a for-profit company?Keach Hagey: Maybe you and Sam should get together and hash that out. That's the kind ofAndrew Keen: Well Sam, I'm available to be hired if you're watching. I'll probably charge less than your current consigliere. What's his name? Who's the consiglieri who's working with him on this?Keach Hagey: You mean Chris Lehane?Andrew Keen: Yes, Chris Lehane, the ego.Keach Hagey: Um,Andrew Keen: How's Lehane holding up in this? Do you think he's getting any sleep?Keach Hagey: Well, he's like a policy guy. I'm sure this has been challenging for everybody. But look, you are pointing to something that I think is real, which is there will probably be consolidation at some point down the line in AI.Andrew Keen: I mean, I know you're not an expert on the maybe sort of corporate legal stuff, but is it in theory possible to buy a nonprofit? I don't even know how you buy a non-profit and then turn it into a for-profit. I mean is that one way out of this, this cul-de-sac?Keach Hagey: I really don't know the answer to that question, to be honest with you. I can't think of another example of it happening. So I'm gonna go with no, but I don't now.Andrew Keen: There are no equivalents, sorry to interrupt, go on.Keach Hagey: No, so I was actually asking a little bit, are there precedents for this? And someone mentioned Blue Cross Blue Shield had gone from being a nonprofit to a for-profit successfully in the past.Andrew Keen: And we seem a little amused by that. I mean, anyone who uses US health care as a model, I think, might regret it. Your book, The Optimist, is out in a couple of weeks. When did you stop writing it?Keach Hagey: The end of December, end of last year, was pencils fully down.Andrew Keen: And I'm sure you told the publisher that that was far too long a window. Seven months on Silicon Valley is like seven centuries.Keach Hagey: It was actually a very, very tight timeline. They turned it around like incredibly fast. Usually it'sAndrew Keen: Remarkable, yeah, exactly. Publishing is such, such, they're such quick actors, aren't they?Keach Hagey: In this case, they actually were, so I'm grateful for that.Andrew Keen: Well, they always say that six months or seven months is fast, but it is actually possible to publish a book in probably a week or two, if you really choose to. But in all seriousness, back to this question, I mean, and I want everyone to read the book. It's a wonderful book and an important book. The best book on OpenAI out. What would you have written differently? Is there an extra chapter on this? I know you warned about a lot of this stuff in the book. So it must make you feel in some ways quite vindicated.Keach Hagey: I mean, you're asking if I'd had a longer deadline, what would I have liked to include? Well, if you're ready.Andrew Keen: Well, if you're writing it now with this news under your belt.Keach Hagey: Absolutely. So, I mean, the thing, two things, I guess, definitely this news about the for-profit conversion failing just shows the limits of Sam's power. So that's pretty interesting, because as the book was closing, we're not really sure what those limits are. And the other one is Trump. So Trump had happened, but we do not yet understand what Trump 2.0 really meant at the time that the book was closing. And at that point, it looked like Sam was in the cold, you know, he wasn't clear how he was going to get inside Trump's inner circle. And then lo and behold, he was there on day one of the Trump administration sharing a podium with him announcing that Stargate AI infrastructure investment. So I'm sad that that didn't make it into the book because it really just shows the kind of remarkable character he is.Andrew Keen: He's their Zelig, but then we all know what happened to Woody Allen in the end. In all seriousness, and it's hard to keep a straight face here, Keach, and you're trying although you're not doing a very good job, what's going to happen? I know it's an easy question to ask and a hard one to answer, but ultimately this thing has to end in catastrophe, doesn't it? I use the analogy of the Titanic. There are real icebergs out there.Keach Hagey: Look, there could be a data breach. I do think that.Andrew Keen: Well, there could be data breaches if it was a non-profit or for-profit, I mean, in terms of this whole issue of trying to have it both ways.Keach Hagey: Look, they might run out of money, right? I mean, that's one very real possibility. They might run outta money and have to be bought by someone, as you said. That is a totally real possibility right now.Andrew Keen: What would happen if they couldn't raise any more money. I mean, what was the last round, the $40 billion round? What was the overall valuation? About $350 billion.Keach Hagey: Yeah, mm-hmm.Andrew Keen: So let's say that they begin to, because they've got, what are their hard costs monthly burn rate? I mean, it's billions of just.Keach Hagey: Well, the issue is that they're spending more than they are making.Andrew Keen: Right, but you're right. So they, let's say in 18 months, they run out of runway. What would people be buying?Keach Hagey: Right, maybe some IP, some servers. And one of the big questions that is yet unanswered in AI is will it ever economically make sense, right? Right now we are all buying the possibility of in the future that the costs will eventually come down and it will kind of be useful, but that's still a promise. And it's possible that that won't ever happen. I mean, all these companies are this way, right. They are spending far, far more than they're making.Andrew Keen: And that's the best case scenario.Keach Hagey: Worst case scenario is the killer robots murder us all.Andrew Keen: No, what I meant in the best case scenario is that people are actually still without all the blow up. I mean, people are actual paying for AI. I mean on the one hand, the OpenAI product is, would you say it's successful, more or less successful than it was when you finished the book in December of last year?Keach Hagey: Oh, yes, much more successful. Vastly more users, and the product is vastly better. I mean, even in my experience, I don't know if you play with it every day.Andrew Keen: I use Anthropic.Keach Hagey: I use both Claude and ChatGPT, and I mean, they're both great. And I find them vastly more useful today than I did even when I was closing the book. So it's great. I don't know if it's really a great business that they're only charging me $20, right? That's great for me, but I don't think it's long term tenable.Andrew Keen: Well, Keach Hagey, your new book, The Optimist, your new old book, The Optimist: Sam Altman, Open AI and the Race to Invent the Future is out in a couple of weeks. I hope you're writing a sequel. Maybe you should make it The Pessimist.Keach Hagey: I think you might be the pessimist, Andrew.Andrew Keen: Well, you're just, you are as pessimistic as me. You just have a nice smile. I mean, in all reality, what's the most optimistic thing that can come out of this?Keach Hagey: The most optimistic is that this becomes a product that is actually useful, but doesn't vastly exacerbate inequality.Andrew Keen: No, I take the point on that, but in terms of this current story of this non-profit versus profit, what's the best case scenario?Keach Hagey: I guess the best case scenario is they find their way to an IPO before completely imploding.Andrew Keen: With the assumption that a non-profit can do an IPO.Keach Hagey: That they find the right lawyers from wherever they are and make it happen.Andrew Keen: Well, AI continues its hallucinations, and they're not in the product themselves. I think they're in their companies. One of the best, if not the best authority, our guide to all these hallucinations in a corporate level is Keach Hagey, her new book, The Optimist: Sam Altman, Open AI and the Race to Invent the Future is out in a couple of weeks. Essential reading for anyone who wants to understand Sam Altman as the consummate salesman. And I think one thing we can say for sure, Keach, is this is not the end of the story. Is that fair?Keach Hagey: Very fair. Not the end of the story. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit keenon.substack.com/subscribe

Journey to a Million Miles: The Stevens Driving Academy Explore the journey to logging a million miles as a trucker with Trucker Tim and Robert Wall, the school director at Stevens Driving Academy. Discover the essential steps from enrollment to graduation at the renowned Dallas, Texas campus. Understand why Stevens Transport is a top choice for aspiring drivers, with a focus on safety, expert training, and strong mentorship. Learn the ins and outs of the four-week course that propels students toward a promising trucking career. Prepare for orientation and a lucrative future on the road as part of Stevens' celebrated workforce. Stevens Transport May News Bulletin Stevens Transport News Bulletin celebrates Stevens Transport's recognition by Ecolab with the 2024 Outstanding Partnership Award, reflecting excellence and collaboration since 2022. Congratulatory highlights include Jeremiah Matthew, a standout student receiving the Truckload Carriers Association Scholarship and dual graduation honors, set to attend UT Dallas. Additionally, Stevens Transport announces a switch to Blue Cross Blue Shield for medical insurance, enhancing benefits for employees. Stay informed with these key industry updates and achievements that pave the way for future success. Become a Team Driver for Stevens Transport Discover the transformative world of team driving with Stevens Transport in this insightful discussion. Learn how driving with a partner boosts efficiency, earning potential, and safety, while allowing for nearly constant travel and the enjoyment of America's stunning landscapes. Understand how federal regulations intersect with teamwork logistics, enabling over 5,500 miles a week. Insights on rest strategies, like bunk bed sleeping arrangements, are shared. Stevens Transport explains the advantages of choosing your driving partner and how this approach can elevate your trucking career. Explore team driving's benefits and start your journey to success now. Earn More/Team Up - https://vimeo.com/1020240977 Driver Spotlight: Raymond Hatchett Jr. Meet Stevens contract driver and trainer Raymond Hatchett Jr.! Raymond shares the journey he's taken from military service to transitioning to a civilian career, highlighting the importance of being patient and working hard, while feeling grateful for the opportunity to teach the next generation of truck drivers. See the video here: https://www.youtube.com/watch?v=LZw97xNFoSo Stevens Spotlight: Uncovering Jim Kant's Passion for Life and Work In this episode of Stevens Spotlight, Tim Cicciarelli chats with James Kant, Senior Safety Supervisor at Stevens Transport, known for his extensive career journey and real-life adventure stories. James shares insights about starting a new career at 52, finding joy in training others, and the wonders of exploring the U.S. with his wife. Discover his unique taste experiences and fun anecdotes, including amusing takes on spaghetti with hot dogs and an unexpected Porsche purchase. Dive into Jim's vibrant world and get inspired by his life's exciting turns and lessons. Pilot/Flying J Rewards App: https://pilotflyingj.com/rewards Become a Driver for Stevens Transport For questions on whether you meet our driver qualifications, please call our Recruiting Department at 1-800-333-8595 or visit: www.stevenstransport.com/drivers/ Stevens Transport 9757 Military Parkway, Dallas, TX 75227 http://www.stevenstransport.com/ http://www.becomeadriver.com/ Driver Recruiting: 1-800-333-8595.  Apply Here: https://intelliapp2.driverapponline.com Paragon Leasing Technician Careers: https://www.stevenstransport.com/careers/fleet-maintenance-jobs/ Stevens Transport on Facebook: https://www.facebook.com/StevensTransport

Medecision is solving foundational healthcare problems by making data actionable in real time through personalized health journeys.  In this episode, Mark Gee, Chief Growth Officer at Medecision, discusses how his company is disrupting healthcare data through real-time insights and action. By re-architecting their enterprise platform, Ariel, they've broken down data silos and enabled operationalized insights at scale, moving beyond traditional data lakes. Their system's ability to accept and process any data format in real time allows for hyper-personalized care journeys that shift focus from reactive to proactive care, evidenced by a 64% engagement increase in a Blue Cross Blue Shield health plan's behavioral health program. Additionally, Medecision is redesigning care and utilization management processes to improve productivity and proactively assist patients. Tune in and learn how real-time data and personalized care journeys are transforming healthcare! Resources: Connect with and follow Mark Gee on LinkedIn. Follow Medecision on LinkedIn and visit their website.

Welcome to the Health Marketing Collective, where strong leadership meets marketing excellence. In today's episode, host Sara Payne sits down with Mike Cronin, Cofounder and Chief Strategist at Verve, to explore the evolving landscape of creativity in B2B healthcare marketing. Mike, whose impressive résumé includes brand and campaign strategy for UnitedHealth Group, Blue Cross Blue Shield, Optum, and revered consumer brands like Harley-Davidson and Samuel Adams, brings a rare blend of creative vision and strategic rigor to his work. His fundamental belief? That creative work's purpose is to move people, not just fill space. In this conversation, Mike and Sara dive deep into how B2B health brands can move beyond “safe” ideas and unlock emotionally resonant, unforgettable campaigns—even within highly regulated and risk-averse spaces. They discuss why simplicity is a superpower, the importance of strategic “boxes,” and how marketing leaders can create environments where big swings are encouraged, not stifled. Along the way, Mike shares memorable stories from his work (including a campaign that fused Lizzo's “Good as Hell” into healthcare advertising), offers insight into the universal human truths marketers often miss, and outlines what separates teams that produce great creative from those that simply make noise. Thank you for being part of the Health Marketing Collective, where strong leadership meets marketing excellence. The future of health care depends on it. Key Takeaways: Creativity Thrives Within Constraints: Mike challenges the conventional wisdom of “thinking outside the box.” He argues that true creativity is often unlocked not by limitless freedom, but by well-defined strategic constraints. It's within the confines of a focused brief—what Mike calls “the freedom of a tight brief”—that intelligent, emotionally resonant ideas emerge. Rather than aiming for “crazy” or “flashy,” the best creative is smart, intentional, and purpose-driven. Emotion and Human Truth are Universal, Even in B2B: B2B often gravitates toward rational benefits: cost savings, efficiency, or productivity. But, as Mike notes, even financial administrators and clinicians are humans first—they respond to messages that tap into universal emotions and experiences: hope, fear, dignity, and relief from frustration. Brands that connect on this human level, rather than just touting features and benefits, become memorable and meaningful. Strategic Alignment is the Key to Unlocking Great Creative: Teams that produce truly breakthrough work consistently prioritize strategy. When everyone is aligned on the core insight and brief, creativity can flow freely within those parameters. Conversely, weak or vague direction leads to “safe,” generic campaigns. Mike's experience shows that great creative always starts with a shared, sharp strategic foundation. Boldness is Essential for Breaking Through the Noise: Healthcare, especially B2B, often defaults to playing it safe (“everything's blue”)—but in a crowded marketplace, standing out is non-negotiable. Mike advocates for boldness that is grounded in the brand's truth and strategically anchored. The result: unforgettable, not just noisy, marketing. Leadership's Role: Foster Honesty, Empathy, and Trust: Leadership sets the tone for creativity and trust. Mike urges CMOs and marketing leaders to lead with clarity and honesty—eschewing “BS” and toxic positivity for real, truthful dialogue about challenges and opportunities. Teams (and audiences) respond to authenticity; when leaders call things as they are and create space for truth, better work results. Resources and Contact: Want to connect with Mike or learn more about Verve's approach to strategic creativity? Visit

Listen to an all-new NWABJ Report for 4.27.25 with Roby Brock featuring an interview with the CEO of Arkansas Blue Cross Blue Shield Curtis Barnett. 

Get ready to travel the world—without leaving your headphones!

No matter what you think about aging, one thing is for sure: EVERYbody's doing it!It's also true that in the U.S., people are living longer, and overall, healthier, more active and empowered than ever in our country's history.It's not uncommon to have three, four, or even five generations in the same family or workplace.According to the last U.S. Census, adults in Tennessee over 60 make up 23% of the population. That's about one in 5 people — and growing.This rapid demographic shift is changing conversations around aging. Starting with this first episode, we join that discussion with a new series titled “Next Age.” Once a month, we'll bring you stories and information about growing older in the 21st century — and how Middle Tennesseans are reframing aging.Our show is made possible by Blue Cross Blue Shield of Tennessee and our series on aging is made possible by a grant from The West End Home Foundation — enriching the lives of older adults though grantmaking, advocacy and community collaboration.GUESTS: Patricia D'Antonio, Executive Director, Center to Reframe Aging Rhonda Cherry, member, Fifty Forward Ralph Bristol, member, Fifty Forward Jon Wellington, co-founder, GenX Takeover Sallie Hussey, Chief Executive Officer, Fifty Forward Dr. James Powers, geriatrician/researcher/professor, VUMC Division of Geriatric Medicine

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to outcomesrocket.com Transforming mental healthcare through personal stories and innovative solutions is pivotal in enhancing access for all. In this episode, Dr. Mike Franz, Executive Medical Director for Behavioral Health at Regence BlueCross BlueShield of Oregon, shares his personal battles with depression and anxiety, illustrating how these experiences shape his empathetic approach to patient care. He emphasizes the significance of effective treatment, highlighting therapy, medication, and the need to destigmatize mental health issues. Dr. Franz discusses the interdependence of mental and physical health, showcasing the accessible services his health plan offers, such as rapid access to psychiatrists and therapists. He encourages leaders to openly share their mental health journeys to help reduce stigma and foster a more supportive environment. Tune in to discover how Dr. Franz is transforming behavioral health care, breaking down barriers to access, and inspiring inclusive solutions for everyone! Resources: Connect with and follow Dr. Mike Franz on LinkedIn. Follow Behavioral Health Tech on LinkedIn and explore their website.  Fast Track Your Business Growth: Outcomes Rocket is a full-service marketing agency focused on helping healthcare organizations like yours maximize your impact and accelerate growth. Learn more at outcomesrocket.com

This week we bring you a series of stories from our public radio partners around New England exploring how the region's flora, fauna and fungi are living with climate change. Plus lawmakers are trying to make a contingency plan in case the only Vermont-based health insurance company, Blue Cross Blue Shield, goes under. And Vermont's unemployment rate holds steady, a new soil testing center for farmers opens at UVM, and where to watch trout travel upstream.

In this episode, Lissa Jones welcomes playright Pearl Cleage back to Black Market Reads as they talk about her play The Nacirema Society Requests the Honor of Your Presence at a Celebration of Their First 100 Years, playing at the Guthrie Theater in Minneapolis April 19-May 29, 2025. SYNOPSIS Grande dames Grace Dunbar and Catherine Green prepare for the Nacirema Society's 1964 centennial cotillion — the event of the season in Montgomery, Alabama. The elegant African American debutantes include Grace's granddaughter Gracie, escorted by Catherine's grandson Bobby, and the two grandmothers hope the young couple will soon be engaged. But Gracie and Bobby have other ideas. As the young ladies prepare for their debuts, a blackmail scheme brews behind the scenes and subterfuges unfold, all under the nose of a skeptical reporter covering the ball. Featuring clever storytelling and scandalous plots, this lighthearted comedy winds its way to an ending as charming as its characters.  Our production team for this episode includes co producers Lissa Jones and Edie French, technical director Paul Auguston, the voice Yo Derek, and our artist of inspiration Ta-coumba T. Aiken. We thank Blue Cross Blue Shield of Minnesota for supporting this series focusing on the intersection of health, race, and culture. This is Black Market Reads. 

Part 1:We talk with T. Christian Miller, reporter for ProPublica.We discuss the case currently in Louisiana courts. Blue Cross/Blue Shield is appealing a judgement that was rendered by a jury after 18 years of litigation. The Jury was out for two hours of deliberation. The case covered "prior authorization" for procedures which BC/BS refused to pay, even after authorization was given. Many interesting arguments were presented by BC/BS to avoid payment. A story of bad faith by the health insurer.Part 2:We talk with Regina Mahone, Senior Editor at The Nation.Regina describes the painful story of a young woman who was denied timely medical care in Georgia, due to its anti-abortion law. The woman, Amber Nicole Thurman, died of sepsis because of delay in treatment. The case was reviewed by a state Board, but the results of the review were not made public, and the Review Board was dismissed. New Board members' names are now secret. In Texas, that Review Board is also keeping names of Board members secret, as well as keeping results secret.We discuss the problems caused by this secret-keeping of the treatment of women's health denial and consideration. We note that Black women are three to four times as likely to die from these kinds medical neglect. Anti-abortion laws in these states are exacerbating these problems for women's health.  Music: From David Rovics, “The Richest Man in the World Says So”, 2025WNHN.ORG production

This is a show about the challenges of getting health insurance and understanding health insurance and paying for health insurance and using health insurance…even for those of us without major medical challenges. It stars my friends Justin Lander and Kaye.The show is sponsored by East Hill Tree Farm, a tree nursery in Plainfield, Vermont.  The nursery opens on April 18th with bare-root trees and shrubs for sale. They're awesome. Go there. 

This episode's Community Champion Sponsor is Ossur. To learn more about their ‘Responsible for Tomorrow' Sustainability Campaign, and how you can get involved: CLICK HEREEpisode Overview: The future of healthcare lies in shifting from reactive treatment to predictive prevention, and our next guest is leading this transformation. Jim Kean, CEO of Molecular You, is harnessing molecular medicine and AI to identify health risks before they progress to disease. With an impressive track record as a serial healthcare entrepreneur, Jim pioneered online health communities with Sapient Health Network (later WebMD), revolutionized direct-to-consumer diagnostics with WellnessFX, and now leads Molecular You in expanding access to precision health insights. Join us to discover how Jim's unique perspective from seven startups and time in the healthcare insurance industry is helping navigate the complex healthcare landscape while driving innovation that can save both money and lives. Let's go!Episode Highlights:Technology detected early-stage pancreatic cancer through molecular pattern changes years before symptoms appearedPlatform analyzes 280+ biomarkers from a single blood sample with plans to expand to 825 markersAI identifies "risk signatures" for conditions like Alzheimer's with 95% accuracyCan determine different biological pathways leading to the same disease, enabling personalized treatments25% of all healthcare expenses will come from just 3% of people who will develop severe disease but aren't yet identifiedAbout our Guest: Jim Kean, CEO of Molecular You, is a technology executive known for driving innovation in consumer health and wellness platforms. At Molecular You, Jim is focused on expanding access to precision health insights that empower proactive healthcare decisions.Before joining Molecular You, Jim was General Manager of the Consumer Platform for Cambia Health, a Blue Cross Blue Shield insurer based in Portland, Oregon, where he drove the development of a next-generation platform for omni-channel consumer engagement. Later, he became General Manager of Value Management, focusing on population health analytics. As Founder and former CEO of WellnessFx™, Jim led the company to become a leader in direct-to-consumer health diagnostics; after founding the company In 2010, he sold it to Thorne (THRN) in 2013 for $25m.In 1995, Jim founded Sapient Health Network (SHN), pioneering online consumer health communities. SHN merged with WebMD in 1999, forming the platform that now attracts over 23 million monthly visitors. He successfully exited the company, turning a $5m investment into $187m in 3.5 years.Former Board Member of Portland Center Stage (PCS) – a highly regarded regional theatre. During his tenure as Treasurer and Chair of the Finance Committee, PCS achieved recognition for developing and opening the first Platinum LEED performing arts building. An avid outdoorsman, in 1999, he hiked the Pacific Crest Trail from Mexico to Canada. He graduated in 1984 from Lewis & Clark College in Portland, OR, and earned an MBA from Tuck School at Dartmouth in 1991. He enjoys the great outdoors and winter sports with his wife and three children. Links Supporting This Episode: Molecular You Website: CLICK HEREJim Kean LinkedIn page: CLICK HEREMolecular You LinkedIn:

April 14, 2025 ~ Tricia Keith, President and CEo of Blue Cross Blue Shield of Michigan joins Tony Michaels and Rachel Stewart live at the Detroit Economic Club.

DESPITE MY DENTIST TRYING TO KILL ME… I GAVE Y'ALL ALL THE HOT TOPICS!   The entire day was me fighting for my life… aka waiting for my mouth to stop being numb from back-to-back dentist appointments. But guess what? STILL I RISE! Because I've got some hot topics to cover, including: Porsha's new YouTube channel and all of the stories that stemmed from it, Brit Eady speaks, Kenya gets on the defensive, Kanye West “apologizes,” a potential Potomac return, more WAGS to Riches MESS, Kyle Richards being a Karen in Encino, and so much more!   Listen to Brit Eady on Housewives Nightcap! Is Candiace Dillard Returning to Potomac? Watch Porsha's first two YouTube videos here! TMZ says Kyle Richards is fighting on behalf on dogs everywhere!   Also—check me out on the latest episode of Mocha Minutes! If you're listening to this on the day it releases, come watch Emily and I on Up And Adam! LIVE!   *** HEY! Some of you have asked how you can show your appreciation for all the content provided by your mama's favorite Black geek. How about you buy me a beer/coffee? CLICK HERE TO SUPPORT! ***   New episodes of “I Ken Not with Kendrick Tucker” are released weekly!   DON'T FORGET TO SUBSCRIBE, RATE, AND REVIEW! I LOVE 5 STARS! EMAIL ME AT IKENNOTPODCAST@GMAIL.COM! FOLLOW ME ON INSTAGRAM! FOLLOW ME ON THREADS! Learn more about your ad choices. Visit megaphone.fm/adchoices

From aging to genetics, we're exploring the balance between nutrition and metabolism in this four-part series.On this episode, Chuck Gaidica is joined by Registered Dietitian for Blue Cross Blue Shield of Michigan, Shanthi Appelö. Together, they explore the science behind nutrient timing.In this episode of A Healthier Michigan Podcast, we explore:What is nutrient timing?How intermittent fasting can have benefits like reducing calorie intake and stabilizing insulin levels, but prolonged fasting may slow metabolism.How timing certain nutrients, like having protein at breakfast or lighter meals in the evening, can help manage energy levels and digestion throughout the day.How developing a regular eating pattern and being mindful of hunger cues can support healthy weight maintenance over time.

This Day in Legal History: Patent Act of 1790On April 10, 1790, the United States passed its first patent law, the Patent Act of 1790, laying the groundwork for a legal framework that would protect inventors and promote innovation. This early legislation granted inventors the exclusive right to their discoveries for a period of 14 years, provided the invention was deemed "useful and important." It was signed into law by President George Washington and represented one of the earliest legal efforts by the new republic to encourage economic growth through technological advancement. The law established a board composed of the Secretary of State, the Secretary of War, and the Attorney General, who were tasked with reviewing patent applications and deciding whether to approve them.Notably, the law gave the federal government broad discretion over what could be patented and required that a patent be granted only if the invention was new and useful. The first U.S. patent under this act was issued on July 31, 1790, to Samuel Hopkins for a process of making potash, a key industrial chemical. Although modest in scope, the law was revolutionary in its recognition of intellectual property as a public good worth safeguarding. It helped move the United States toward a more structured innovation economy, setting a precedent that influenced global norms on patent protection.The 1790 law was replaced just three years later by the Patent Act of 1793, which shifted the review process to a more administrative function, but the foundational principle—that inventors should have exclusive rights to their creations—remained intact. This early commitment to fostering invention through legal means helped spur the rapid technological growth that would define American industry in the 19th century and beyond. The act exemplified how the law could be used to incentivize creativity and economic development at a national scale.Bristol Myers Squibb successfully got a proposed class action lawsuit dismissed that had accused it of using fraudulent tactics to maintain a monopoly over its cancer drug, Pomalyst. The suit, led by Blue Cross Blue Shield of Louisiana, claimed that Bristol Myers and its subsidiary Celgene illegally secured patents and filed sham lawsuits to delay the entry of generic versions of Pomalyst, which is used to treat multiple myeloma. However, U.S. District Judge Edgardo Ramos ruled that the plaintiffs failed to prove that any of the six patents were obtained through fraud. He also found no evidence that the nine lawsuits Celgene filed between 2017 and 2020 against generic manufacturers like Teva and Mylan were baseless or intended to secure fraudulent settlements.The plaintiffs alleged that they had been overpaying for the drug since October 2020, the point at which generics could have entered the market if not for the alleged conduct. Pomalyst brought in $3.55 billion in sales in 2024, accounting for more than 7% of Bristol Myers' revenue. Celgene originally developed the drug, and Bristol Myers acquired the company in 2019. The case was heard in the U.S. District Court for the Southern District of New York.Bristol Myers wins dismissal of lawsuit alleging Pomalyst monopoly | ReutersThe Trump administration has frozen over $1 billion in federal funding for Cornell University and $790 million for Northwestern University amid investigations into alleged civil rights violations. The freeze affects grants and contracts from several federal agencies, including health, education, agriculture, and defense. This move is part of a broader crackdown targeting universities over pro-Palestinian campus protests, diversity programs, and transgender policies. The administration previously warned 60 universities, including Cornell and Northwestern, about potential enforcement if they failed to address what it labeled as antisemitism.Cornell confirmed it received “stop work” orders from the defense department affecting research projects but said it hasn't been formally notified of the total funding freeze. Northwestern similarly acknowledged awareness of media reports but stated it hadn't received official notice. The university emphasized the freeze could endanger critical research, including projects on cybersecurity, pacemakers, and Alzheimer's treatment.This action follows similar measures taken against Harvard, Princeton, Columbia, and the University of Pennsylvania. Columbia, which lost $400 million in funding, later agreed to administrative changes in exchange for potential reinstatement. Federal agents have also begun detaining and deporting some foreign student protesters, revoking visas in the process. Critics, including human rights groups, have voiced concerns over free speech, academic freedom, Islamophobia, and anti-Arab discrimination amid the escalating response to pro-Palestinian activism on campuses.US freezes funding for Cornell, Northwestern University in latest crackdownPresident Trump has issued a new executive order aimed at blocking state-level climate policies that seek to reduce fossil fuel use and limit carbon emissions. The directive instructs the U.S. attorney general to identify and challenge state laws related to climate change, environmental justice, ESG (environmental, social, and governance) standards, and carbon regulation. The move aligns with Trump's broader agenda to boost domestic fossil fuel production and roll back Democratic-led environmental initiatives.The order specifically targets policies in states like New York, Vermont, and California, including financial penalties on fossil fuel companies, California's cap-and-trade system, and climate-related lawsuits brought by state governments. Trump described these measures as ideologically driven and harmful to national energy and economic security.Governors Kathy Hochul (NY) and Michelle Lujan Grisham (NM), co-chairs of the U.S. Climate Alliance, condemned the order, asserting states' rights to enact environmental protections. They reaffirmed their commitment to clean energy and climate resilience. The American Petroleum Institute supported Trump's move, framing it as a defense against unconstitutional state actions that burden oil and gas companies.Trump issues order to block state climate change policies | Reuters This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

In this episode Lissa talks with Dr. Gail C. Christopher —a nationally recognized leader in health equity, a pioneer in integrative medicine, and the visionary architect behind the Truth, Racial Healing, and Transformation initiative (TRHT). Dr. Christopher has spent decades designing and leading national programs that advance racial healing, community well-being, and policy change—including her role as Senior Advisor and Vice President at the W.K. Kellogg Foundation. She is also the Executive Director of the National Collaborative for Health Equity. She joins us today to discuss her new book, Rx Racial Healing: A Guide to Embracing Our Humanity—a guidebook, a meditation, and a call to action all in one. For GO DEEPER information, Visit: www.BlackMarketReads.com   Our production team for this episode includes co producers Lissa Jones and Edie French, technical director Paul Auguston, the voice Yo Derek, and our artist of inspiration Ta-coumba T. Aiken. Black Market Reads is a production of the Givens Foundation for African American Literature produced in cooperation with iDream.tv. We thank Blue Cross Blue Shield of Minnesota for supporting this series, focusing on the intersection of health, race, and culture. This is Black Market Reads. The struggle continues.

Trump's Liberation Day Tariff ChaosPanic grips the White House as Trump's erratic Liberation Day tariff plans, set for April 2nd, spiral into chaosCar Crisis Unleashed: Trump's Tariffs Jack Prices to the Moon and Trump “couldn't care less”Musk's Mega WinCongress surrenders as Trump seizes tariff reins, spitting on the founders' wisdomDrug Czar Farce: Trump's Pick Shields CIA's Dirty Secrets Silencing Dissent: Dr. Sam Bailey's License Ripped for Defying COVID LiesNew Zealand's Dr. Sam Bailey, MD pays a brutal price—$90,000 fine and license yanked—for daring to question PCR and Trump's shots! And in Canada, a detective is punished for investigating SIDS (Sudden Infant Death Syndrome).  Don't look at SIDS or autism! Green Heist: GOP Loves Biden's $4 Trillion Green Tax Credits King Trump's Gambit: Constitution Be Damned for a Third Term“I'm not joking” says Trump about a third term Pardon Payoff Scandal: Trump Cashes In on Criminals Like MiltonParadise Found (or bought) by Milton.  Trump's pardon for Nikola's fraudster Milton after a cool $2 million campaign gift! Whistleblowers like Kiriakou reported Giuliani selling Trump pardons, while big-tech crooks buy freedom. Satan's Siege: Churches Vandalized, Black Mass in KansasThe Satanists' strategy and why their claims of “religious equality” should be ignored Schools, Satanists, and the First Amendment ClashOklahoma fights to reclaim religious rights in schools, while Satanists push abortion pills and Daily Wire's attempt to gag “Christ is King” becomes an Easter tradition.  From Kenya murders to Idaho lawsuits, faith faces a multi-front war Bodyoid Horror: MIT's Trial Balloon to Grow Humans for Parts Unleashes Ethical HellMIT floats a nightmare—grow “bodyoids” in labs for drugs, organs, maybe meat! No pain, no brains, they claim, but the transhumanist abyss yawns wide. Is this science or a soulless descent into Brave New World? Vaccine Reckoning: Mixed Signals Whether Justice Will Prevail     Dr. Vernon Coleman drops a bombshell—doctors who pushed COVID shots could be bankrupt by 2030?     Yet Tennessee's Supreme Court stabs workers in the back, siding with Blue Cross Blue Shield to fire the unvaccinated Greenland MAGA: “Make America GO AWAY”     Trump's Greenland obsession turns icy as Trump's chilling statement — “a good POSSIBILITY that we could do it without military force” is an implied threat of military force     And, Panama Port Power Play as China shuts down the deal with antitrust probes “The Who”, Roger Daltry, says he's going blind & deaf — but he still plays a mean pinball and helps with teen cancer charity as he reflects on aging JFK Bombshell: Alleged NBC's Secret Tape Could Expose Oswald's Innocence What's Behind the Drop in Egg Prices? Mug-Shot! Too Much Coffee in Texas Could Get You a DUI (Driving Under Influence)If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Money should have intrinsic value AND transactional privacy: Go to DavidKnight.gold for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to TrendsJournal.com and enter the code KNIGHTFor 10% off supplements and books, go to RNCstore.com and enter the code KNIGHTBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

Trump's Liberation Day Tariff ChaosPanic grips the White House as Trump's erratic Liberation Day tariff plans, set for April 2nd, spiral into chaosCar Crisis Unleashed: Trump's Tariffs Jack Prices to the Moon and Trump “couldn't care less”Musk's Mega WinCongress surrenders as Trump seizes tariff reins, spitting on the founders' wisdomDrug Czar Farce: Trump's Pick Shields CIA's Dirty Secrets Silencing Dissent: Dr. Sam Bailey's License Ripped for Defying COVID LiesNew Zealand's Dr. Sam Bailey, MD pays a brutal price—$90,000 fine and license yanked—for daring to question PCR and Trump's shots! And in Canada, a detective is punished for investigating SIDS (Sudden Infant Death Syndrome).  Don't look at SIDS or autism! Green Heist: GOP Loves Biden's $4 Trillion Green Tax Credits King Trump's Gambit: Constitution Be Damned for a Third Term“I'm not joking” says Trump about a third term Pardon Payoff Scandal: Trump Cashes In on Criminals Like MiltonParadise Found (or bought) by Milton.  Trump's pardon for Nikola's fraudster Milton after a cool $2 million campaign gift! Whistleblowers like Kiriakou reported Giuliani selling Trump pardons, while big-tech crooks buy freedom. Satan's Siege: Churches Vandalized, Black Mass in KansasThe Satanists' strategy and why their claims of “religious equality” should be ignored Schools, Satanists, and the First Amendment ClashOklahoma fights to reclaim religious rights in schools, while Satanists push abortion pills and Daily Wire's attempt to gag “Christ is King” becomes an Easter tradition.  From Kenya murders to Idaho lawsuits, faith faces a multi-front war Bodyoid Horror: MIT's Trial Balloon to Grow Humans for Parts Unleashes Ethical HellMIT floats a nightmare—grow “bodyoids” in labs for drugs, organs, maybe meat! No pain, no brains, they claim, but the transhumanist abyss yawns wide. Is this science or a soulless descent into Brave New World? Vaccine Reckoning: Mixed Signals Whether Justice Will Prevail     Dr. Vernon Coleman drops a bombshell—doctors who pushed COVID shots could be bankrupt by 2030?     Yet Tennessee's Supreme Court stabs workers in the back, siding with Blue Cross Blue Shield to fire the unvaccinated Greenland MAGA: “Make America GO AWAY”     Trump's Greenland obsession turns icy as Trump's chilling statement — “a good POSSIBILITY that we could do it without military force” is an implied threat of military force     And, Panama Port Power Play as China shuts down the deal with antitrust probes “The Who”, Roger Daltry, says he's going blind & deaf — but he still plays a mean pinball and helps with teen cancer charity as he reflects on aging JFK Bombshell: Alleged NBC's Secret Tape Could Expose Oswald's Innocence What's Behind the Drop in Egg Prices? Mug-Shot! Too Much Coffee in Texas Could Get You a DUI (Driving Under Influence)If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Money should have intrinsic value AND transactional privacy: Go to DavidKnight.gold for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to TrendsJournal.com and enter the code KNIGHTFor 10% off supplements and books, go to RNCstore.com and enter the code KNIGHTBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

In this episode, Dr. Steve Friedhoff, Senior VP of Healthcare Services at Blue Cross Blue Shield of North Carolina, discusses innovative initiatives addressing healthcare workforce shortages and expanding access to care. From supporting veterans transitioning into medical careers to investing in youth mental health programs, Dr. Friedhoff highlights how Blue Cross NC is shaping the future of healthcare in the state.

From aging to genetics, we're exploring the balance between nutrition and metabolism in this four-part series.On this episode, Chuck Gaidica is joined by Registered Dietitian for Blue Cross Blue Shield of Michigan, Shanthi Appelö. Together, they explore how the nutritional value of food plays a bigger role than just calorie count.In this episode of A Healthier Michigan Podcast, we explore:How nutrient-dense foods such as vegetables, whole grains, and legumes are high in vitamins, minerals, fiber, and other beneficial nutrients, beyond just calories.How consuming nutrient-dense foods can support overall health, immune function, and disease prevention, beyond just weight management.How it's still possible to overeat even nutrient-dense foods, so calorie awareness is still important.Examples of high-calorie, low-nutrient foods.Calories aren't the full story, but timing our nutrients could be the next big piece of the puzzle. Tune in for our final episode, where we'll break down nutrient timing and if it can optimize our long-term health.

What can leaders learn from the high-pressure world of neonatal intensive care? Dr. Susan Landers, a seasoned neonatologist, joins Matt Poepsel to share insights on handling stress, building resilient teams, and navigating work-life balance. From life-or-death decisions in the NICU to balancing a demanding career and family, Susan's lessons apply to leaders in any field. Tune in for powerful takeaways on teamwork, adaptability, and emotional intelligence.   From Our Sponsor: The Predictive Index (PI) is an award-winning talent optimization platform that aligns business strategy with people strategy for optimal business results. More than 60 years of proven science, software, and a curriculum of insightful management workshops make PI the solution for any company looking to design great teams and culture, make objective hiring decisions, foster engagement, and inspire greatness in their people anywhere in the world. More than 10,000 clients and 480+ partners use PI—including Nissan, Citizens Bank, Subway, Blue Cross Blue Shield, and Omni Hotels—across 90+ countries. Learn more at predictiveindex.com.   Additional Resources: Listen to the original episode on Lead the People Follow PeopleForward Network on LinkedIn Learn more about PeopleForward Network   Key Takeaways: Leadership in Crisis: The NICU is an intense, high-stakes environment where quick decisions and teamwork save lives—similar to leadership in any fast-paced industry. The Power of Teamwork: A well-functioning team includes diverse roles, from doctors to respiratory therapists to lactation consultants. Everyone plays a critical part. Emotional Intelligence is Key: Parents handle stress differently—some shut down, others demand miracles. Leaders must recognize different coping mechanisms and adapt. Work-Life Balance is a Moving Target: Balancing a medical career with motherhood required constant adjustments, clear communication, and strong support systems. The Evolving Workplace: Remote work has changed how professionals connect, making it even more important to foster relationships and support networks.

What if having the right team was the secret to launching big ideas - without burning out? In this episode, I chat with Jen Kem, a Forbes-recognized brand strategist who's worked with powerhouse brands like Oprah Winfrey Network, Oracle, and Blue Cross Blue Shield. She's also an introverted, 8-figure entrepreneur of 2 decades who knows a thing or two about leading with energy and intention.Jen shares insights from her new book, Unicorn Team: The Nine Leadership Types You Need to Launch Your Big Ideas with Speed and Success, breaking down how to build a collaborative, high-performing team that brings your vision to life. Whether you're an entrepreneur, a team leader, or just someone who wants to stop doing all the hard things alone, this episode is for you.We'll also be discussing my own Unicorn Leadership Type Assessment (ULTA®) results so you can see how my own strengths fit into my career and business so far! Tune in to hear:The Unicorn Innovation Model - how top leaders build teams that actually get things doneThe Three Leadership Energies: Visionizer, Strategizer, Mobilizer - and why knowing your score is a game-changerWhy introverts can be incredible leaders - and how to harness your natural strengthsHow to navigate AI and automation shifts - without losing the human touch in businessJen's #1 tip for owning her energy while running an 8-figure business and raising a familyLINKS AND RESOURCES:Unicorn Team: The Nine Leadership Types You Need to Launch Your Big Ideas with Speed and Success by Jen KemJen Kem's WebsiteConnect with Jen on LinkedInCONNECT WITH EMMA-LOUISEWebsite: https://theambitiousintrovert.com/ LinkedIn: https://www.linkedin.com/in/emmalouparkes/Instagram: https://www.instagram.com/emmalouparkesSign up to receive my monthly Introverts Only digest, delivering all the best introvert-friendly resources straight to your inbox, minus the scroll herePREMIUM SUPPORT Interested in working with me 1:1? Start the conversation by completing this short form and I'll be in touch.

Jen Kem is the CEO of Master Brand Institute, a company that helps entrepreneurs build influential and profitable brands. With over 20 years of experience, she has built multiple seven- and eight-figure businesses and consulted for Fortune 500 companies like Verizon and Blue Cross Blue Shield. Jen is also the creator of the Master Brand Method, a framework that leverages brand archetypes to win customers' hearts. Her work has been recognized by Forbes, naming her a top brand strategist, and she has collaborated with iconic brands such as the Oprah Winfrey Network and Oracle. In this episode… Building a successful brand and business isn't just about having a great idea — it's about having the right people to bring it to life. Many entrepreneurs struggle with finding the right team, leading to stalled growth, burnout, and missed opportunities. How can leaders identify and attract the best talent to scale their vision effectively? Renowned brand strategist Jen Kem believes that success starts with understanding leadership energy types and assembling a complementary team. She shares insights on the three concepts the nine leadership energies are based on — visionary, strategist, and mobilizer — and explains how they impact decision-making and execution. Jen emphasizes the importance of self-awareness, strategic hiring, and cultivating relationships to build a team that not only shares the vision but actively drives it forward. Tune in to this episode of the Smart Business Revolution Podcast as John Corcoran interviews Jen Kem, CEO of Master Brand Institute, about harnessing your inner unicorn to elevate your brand. Jen discusses the leadership energy framework, the lessons she learned from scaling and losing an eight-figure business, and the importance of resilience in entrepreneurship. She also shares insights on brand positioning, effective messaging, and what it takes to become a true unicorn in business.

958: How is AI revolutionizing healthcare? In this episode of Technovation, Melissa Flicek, CIO of Blue Cross Blue Shield of Minnesota, joins host Peter High to explore how the nearly 100-year-old healthcare giant is leveraging AI, data analytics, and digital transformation to enhance patient experiences and operational efficiency. With $15B+ in annual revenue, BCBSMN is modernizing its technology infrastructure, implementing AI-powered automation to streamline patient interactions, and consolidating data into a single-source architecture to ensure consistency across all touchpoints. Melissa shares how these innovations are improving customer service, optimizing clinical workflows, and supporting predictive healthcare modeling to help lower costs.

Today's guest is Ylan Kazi, Chief Data and AI Officer at Blue Cross Blue Shield of North Dakota. Ylan returns to the show to discuss the latest developments in AI adoption within healthcare. The conversation explores key obstacles, including cultural resistance, the need for an AI Hippocratic Oath, and the risks of holding AI to unrealistic standards. Ylan also examines how agentic AI—capable of operating across systems to accomplish complex tasks—is reshaping healthcare operations. From optimizing administrative processes to rethinking claims management, AI has the potential to drive efficiency while maintaining human oversight where it matters most. This episode is sponsored by Searce. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.

In this episode, Jakob Emerson, Associate News Director at Becker's Healthcare, joins Scott Becker to discuss the ongoing Medicare Advantage billing investigation into UnitedHealth, the financial struggles of smaller Blue Cross Blue Shield plans, and how these challenges are reshaping the healthcare landscape.

This episode has three chapters. Each one answers a key question, and, bottom line, it all adds up to action steps directly and indirectly for many, including plan sponsors probably, community leaders, and also hospital boards of directors. Here's the three chapters in sum. For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. Chapter 1: Are commercial insurance premiums rising faster than the inflation rate? And if so, is the employee portion of those premiums also rising, meaning a double whammy for employees' paychecks (ie, premium costs are getting bigger and bigger in an absolute sense, and also employees' relative share of those bigger costs is also bigger)? Spoiler alert: yes and yes. Chapter 2: What is the biggest reason for these premium increases? Like, if you look at the drivers of cost that underpin those rising premiums, what costs a lot that is making these premiums cost a lot? Spoiler alert: It's hospitals and the price increases at hospitals. And just in case anyone is wondering, this isn't, “Oh, chargemasters went up” or some kind of other tangential factor. We're talking about the revenue that hospitals are taking on services delivered has gone up and gone up way higher than the inflation rate. In fact, hospital costs have gone up over double the amount that premiums have gone up. Wait, what? That's a fact that Dr. Vivian Ho said today that threw my brain for a loop: Hospital costs have gone up over double the amount that premiums have gone up. Chapter 3: Is the reason that hospital prices have rocketed up as they have because the underlying costs these hospitals face are also going up way higher than the inflation rate? Like, for example, are nurses' salaries skyrocketing and doctors are getting paid a lot more than the inflation rate? Stuff like this. Too many eggs in the cafeteria. Way more charity care. Bottom line, is an increase in underlying costs the reason for rising hospital prices? Spoiler alert: no. No to all of the above. And I get into this deeply with Dr. Vivian Ho today. But before I do, I do just want to state with three underlines not all hospitals are the same. But yeah, you have many major consolidated hospitals crying about their, you know, “razor-thin margins” who are, it turns out, incentivizing their C-suites to do things that ultimately wind up raising prices. I saw a PowerPoint flying around—you may have seen it, too—that was apparently presented by a nonprofit hospital at JP Morgan, and it showed this nonprofit hospital with a 15.1% EBITDA (earnings before interest, taxes, depreciation, and amortization) in 2024. Not razor thin in my book. It's a, the boards of directors are structuring C-suite incentives in ways that ultimately will raise prices. If you want to dig in a little deeper on hospital boards and what they may be up to, listen to the show with Suhas Gondi, MD, MBA (EP404). Vivian Ho, PhD, my guest today, is a professor and faculty member at Rice University and Baylor College of Medicine. Her most major role these days is working on health policy at Baker Institute at Rice University. Her work there is at the national, state, and local levels conducting objective research that informs policymakers on how to improve healthcare. Today on the show, Professor Vivian Ho mentions research with Salpy Kanimian and Derek Jenkins, PhD. Alright, so just one quick sidebar before we get into the show. There is a lot going on with hospitals right now. So, before we kick in, let me just make one really important point. A hospital's contribution to medical research, like doing cancer clinical trials, is not the same as how a hospital serves or overcharges their community or makes decisions that increase or reduce their ability to improve the health and well-being of patients and members who wind up in or about the hospital. Huge, consolidated hospital networks can be doing great things that have great value and also, at the exact same time, kind of harmful things clinically and financially that negatively impact lots of Americans and doing all of that simultaneously. This is inarguable. Also mentioned in this episode are Rice University's Baker Institute for Public Policy; Baker Institute Center for Health Policy; Suhas Gondi, MD, MBA; Salpy Kanimian; Derek Jenkins, PhD; Byron Hugley; Michael Strain; Dave Chase; Zack Cooper, PhD; Houston Business Coalition on Health (HBCH); Marilyn Bartlett, CPA, CGMA, CMA, CFM; Cora Opsahl; Claire Brockbank; Shawn Gremminger; Autumn Yongchu; Erik Davis; Ge Bai, PhD, CPA; Community Health Choice; Mark Cuban; and Ferrin Williams, PharmD, MBA. For further reading, check out this LinkedIn post.   You can learn more at Rice University's Center for Health Policy (LinkedIn) and Department of Economics and by following Vivian on LinkedIn.   Vivian Ho, PhD, is the James A. Baker III Institute Chair in Health Economics, a professor in the Department of Economics at Rice University, a professor in the Department of Medicine at Baylor College of Medicine, and a nonresident senior scholar in the USC Schaeffer Center for Health Policy and Economics. Ho's research examines the effects of economic incentives and regulations on the quality and costs of health care. Her research is widely published in economics, medical, and health services research journals. Ho's research has been funded by the National Institutes of Health (NIH), the Agency for Healthcare Research and Quality, the American Cancer Society, and Arnold Ventures. Ho has served on the Board of Scientific Counselors for the National Center for Health Statistics, as well as on the NIH Health Services, Outcomes, and Delivery study section. She was elected as a member of the National Academy of Medicine in 2020. Ho is also a founding board member of the American Society for Health Economists and a member of the Community Advisory Board at Blue Cross Blue Shield of Texas. Ho received her AB in economics from Harvard University, a graduate diploma in economics from The Australian National University, and a PhD in economics from Stanford University.   05:12 Are insurance premiums going up? 05:59 What is the disparity between cost of insurance and wage increases? 06:21 LinkedIn post by Byron Hugley. 06:25 Article by Michael Strain. 06:46 How much have insurance premiums gone up for employers versus employees? 09:06 Chart showing the cost to insure populations of employees and families. 10:17 What is causing hospital prices and insurance premiums to go up so exponentially? 12:53 Article by (and tribute to) Uwe Reinhardt. 13:49 EP450 with Marilyn Bartlett, CPA, CGMA, CMA, CFM. 14:01 EP452 with Cora Opsahl. 14:03 EP453 with Claire Brockbank. 14:37 EP371 with Erik Davis and Autumn Yongchu. 15:28 Are razor-thin operating margins for hospitals causing these rising hospital prices? 16:56 Collaboration with Marilyn Bartlett and the NASHP Hospital Cost Tool. 19:47 What is the explanation that hospitals give for justifying these profits? 23:16 How do these hospital cost increases actually happen? 27:06 Study by Zack Cooper, PhD. 27:35 EP404 with Suhas Gondi, MD, MBA. 27:50 Who typically makes up a hospital board, and why do these motivations incentivize hospital price increases? 30:12 EP418 with Mark Cuban and Ferrin Williams, PharmD, MBA. 33:17 Why is it vital that change start at the board level?   You can learn more at Rice University's Center for Health Policy (LinkedIn) and Department of Economics and by following Vivian on LinkedIn.   Vivian Ho discusses #healthinsurance #premiums and #hospitalpricing on our #healthcarepodcast. #healthcare #podcast #changemanagement #healthcareleadership #healthcaretransformation #healthcareinnovation   Recent past interviews: Click a guest's name for their latest RHV episode! Chris Crawford (EP465), Al Lewis, Betsy Seals, Wendell Potter (Encore! EP384), Dr Scott Conard, Stacey Richter (INBW42), Chris Crawford (EP461), Dr Rushika Fernandopulle, Bill Sarraille, Stacey Richter (INBW41)